KalVista Pharmaceuticals (STU:4XC1) Current Accrued Expense : €8.61 Mil (As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Current Accrued Expense?

KalVista Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jan. 2024 was €8.61 Mil.

KalVista Pharmaceuticals's quarterly Current Accrued Expense increased from Jul. 2023 (€4.93 Mil) to Oct. 2023 (€7.44 Mil) and increased from Oct. 2023 (€7.44 Mil) to Jan. 2024 (€8.61 Mil).

KalVista Pharmaceuticals's annual Current Accrued Expense declined from Apr. 2021 (€2.86 Mil) to Apr. 2022 (€2.59 Mil) but then increased from Apr. 2022 (€2.59 Mil) to Apr. 2023 (€4.49 Mil).

KalVista Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for KalVista Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Current Accrued Expense Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Current Accrued Expense

Get a 7-Day Free Trial

3.29

2.87

2.86

2.59

4.49

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Current Accrued Expense	Get a 7-Day Free Trial															4.39	4.49	4.93	7.44	8.61

KalVista Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

KalVista Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines